You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
US FDA Clears Neonatal Indication for O3Regional Oximetry
11 June 2019 - - US-based medical technology company Masimo's (NASDAQ: MASI) O3 Regional Oximetry has received FDA clearance for use on neonatal and infant patients (
Login
Username:

Password:


Related Headlines

Genezen agrees manufacturing collaboration with Galibra Neuroscience

FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)

FDA approves Vantis Vascular's 6F CrossFAST model

Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201

ArkBio reports FDA clearance of IND application for AK0406

Agilent to acquire Proscia for up to USD270m to expand digital pathology capabilities

Bristol Myers Squibb reports positive Phase 3 results for RYZ101 in neuroendocrine tumours

US WorldMeds awarded 2026 Vision of Hope Award

Urolution Medical secures FDA clearance for OpenFlo urinary catheter

Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay

Medincell partner Teva secures FDA approval for monthly schizophrenia treatment

FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer

Lupin Limited receives FDA approval for Phytonadione Injectable Emulsion USP

argenx reports positive Phase 2 results for FB102 in coeliac disease

Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026